Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats

International Journal of Cardiology

Volumn 114, Issue 1, 2007, Pages 64-70

  Burla, Adriana K ^a   Neves, Mario Fritsch ^a   Oigman, Wille ^a   Mandarim de Lacerda, Carlos A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Aldosterone; Cardiomyocyte; Collagen; Fibrosis; Hypertension; Stereology

Indexed keywords

ENALAPRIL; EPLERENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; IMAGE ANALYSIS; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STEREOLOGY;

ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; ENALAPRIL; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, WISTAR; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 33751331162     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.007     Document Type: Article

References (42)

1. Struthers A.D. Aldosterone: cardiovascular assault. Am Heart J 144 (2002) S2-S7
2. Kawano H., Do Y.S., Kawano Y., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101 (2000) 1130-1137
3. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14 (2005) 235-241
4. Neves M.F., Virdis A., and Schiffrin E.L. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 21 (2003) 189-198
5. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
6. Neves M.F., and Schiffrin E.L. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 5 (2003) 59-65
7. Rocha R., and Stier Jr. C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 (2001) 308-314
8. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2004) 765-770
9. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., and Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (2004) 558-565
10. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102 (2000) 2700-2706
11. Delyani J.A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 57 (2000) 1408-1411
12. White W.B., Carr A.A., Krause S., Jordan R., Roniker B., and Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92 (2003) 38-42
13. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 (2002) 117-123
14. White W.B., Duprez D., St Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
15. Coats A.J. Exciting new drugs on the horizon-eplerenone, a selective aldosterone receptor antagonist (SARA). Int J Cardiol 80 (2001) 1-4
16. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
17. Scherle W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie 26 (1970) 57-60
18. Mandarim-de-Lacerda C.A. Stereological tools in biomedical research. An Acad Bras Cienc 75 (2003) 469-486
19. Mandarim-de-Lacerda C.A., and Pereira L.M. Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol Histopathol 19 (2004) 727-733
20. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134 Pt 2 (1984)
21. Gundersen H.J., and Osterby R. Optimizing sampling efficiency of stereological studies in biology: or 'do more less well'. J Microsc 121 (1981) 65-73
22. Gundersen H.J., Bagger P., and Bendtsen T.F. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96 (1988) 857-881
23. Lijnen P., and Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32 (2000) 865-879
24. Martinez D.V., Rocha R., Matsumura M., et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39 (2002) 614-618
25. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
26. Amann K., Gharehbaghi H., Stephan S., and Mall G. Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 25 (1995) 124-131
27. Mandarim-de-Lacerda C.A., and Pereira L.M. The effects of spironolactone monotherapy on blood pressure and myocardial remodeling in spontaneously hypertensive rats: a stereological study. J Biomed Sci 10 (2003) 50-57
28. Olivetti G., Melissari M., Capasso J.M., and Anversa P. Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res 68 (1991) 1560-1568
29. Mandarim-de-Lacerda C.A., and Pereira L.M. Numerical density of cardiomyocytes in chronic nitric oxide synthesis inhibition. Pathobiology 68 (2000) 36-42
30. Pessanha M.G., and Mandarim-de-Lacerda C.A. Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number. Virchows Arch 437 (2000) 667-674
31. De Angelis N., Fiordaliso F., Latini R., et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 34 (2002) 1655-1665
32. Tan L.B., Jalil J.E., Pick R., Janicki J.S., and Weber K.T. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 69 (1991) 1185-1195
33. Gonzalez A., Lopez B., Ravassa S., et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 39 (2002) 75-80
34. Kajstura J., Cigola E., Malhotra A., et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29 (1997) 859-870
35. Burniston J.G., Saini A., Tan L.B., and Goldspink D.F. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 39 (2005) 395-399
36. Hamet P., Moreau P., Dam T.V., et al. The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling. J Hypertens Suppl 14 (1996) S65-S70
37. Rocha R., Stier Jr. C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 (2000) 3871-3878
38. Garnier A., Bendall J.K., and Fuchs Jr. S. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110 (2004) 1819-1825
39. Brilla C.G., Matsubara L.S., and Weber K.T. Antialdosterone treatment and prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25 (1993) 563-575
40. Kuster G.M., Kotlyar E., Rude M.K., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111 (2005) 420-427
41. Endemann D.H., Touyz R.M., Iglarz M., Savoia C., and Schiffrin E.L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43 (2004) 1252-1257
42. Park J.B., and Schiffrin E.L. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37 (2001) 1444-1449